Abeona Therapeutics logo
Abeona Therapeutics
ABEO | NASDAQ
Chart Builder DCF Calculator
$2.60
+$0.18 (+7.44%)
At close: Nov 16, 2026, 4:00 PM ET
$2.62
+$0.02 (+0.77%)
After-hours: Nov 16, 2026, 7:30 PM ET

Abeona Therapeutics Company Profile

Company profile explained

Company Profile

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

Key Executives

Name Position
Vishwas Seshadri President, Chief Executive Officer & Director
Brendan O'Malley Chief Legal Officer
Gianine Esposito Senior VP & Chief People Officer
Joseph Walter Vazzano Chief Financial Officer
Brian Kevany Chief Technical & Scientific Officer
Carl Denny Senior Vice President of Regulatory Affairs
Gregory Gin Vice President of Investor Relations & Corporation Communications
Jon Voss Vice President & Head of Quality
Madhav Vasanthavada Senior Vice President, Chief Commercial Officer & Head of Business Development
Megan Callan Vice President & Head of Quality

Latest SEC Filings

Date Type Title
Oct 23, 2026 SC 13D Filing
Sep 29, 2026 4 Filing
Sep 29, 2026 4 Filing
Sep 29, 2026 4 Filing
Sep 29, 2026 4 Filing
Sep 15, 2026 8-K Current Report
Sep 01, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 10-Q Quarterly Report
Aug 13, 2026 8-K Current Report
View All SEC Filings ➞
Abeona Therapeutics
Abeona Therapeutics logo
Country United States
IPO Date Sep 19, 1980
Industry Biotechnology
Sector Healthcare
Employees 226
CEO Vishwas Seshadri

Contact Details

6555 Carnegie Avenue Cleveland, Ohio 44103 United States

Stock Details

Ticker Symbol ABEO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000318306
CUSIP Number 00289Y206
ISIN Number US00289Y2063
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.